Ophthalmic Artificial Intelligence-Assisted Diagnosis Market Report 2025

The ophthalmic artificial intelligence-assisted diagnosis market size has grown rapidly in recent years. It will grow from $1.83 billion in 2024 to $2.17 billion in 2025 at a compound annual growth rate (CAGR) of 18.7%. Growth in the historic period was driven by increasing awareness of early diagnosis for ocular disorders, rising demand for efficient and accurate retinal imaging, higher incidence of diabetic retinopathy, an expanding geriatric population, and greater investment in healthcare infrastructure.

The ophthalmic artificial intelligence-assisted diagnosis market size is expected to see rapid growth in the next few years. It will grow to $4.26 billion in 2029 at a compound annual growth rate (CAGR) of 18.3%. Growth in the forecast period is expected to result from greater use of AI in teleophthalmology, rising demand for remote and accessible eye care solutions, increased focus on preventive eye care, expanding adoption of remote diagnosis, and growing regulatory approvals for AI-based ophthalmic devices. Primary trends anticipated for the forecast period include advancements in deep learning algorithms for retinal image analysis, development of portable and autonomous AI-based eye screening devices, integration of AI diagnostics with electronic health records, innovation in multi-disease detection platforms, and incorporation of AI with telemedicine for remote eye care.

The growing incidence of eye disorders is anticipated to drive the expansion of the ophthalmic artificial intelligence-assisted diagnosis market. Eye disorders are medical conditions that affect the eye's structure or function, leading to potential vision loss or health problems. The increasing use of digital devices is contributing to a rise in these disorders, with more people experiencing digital eye strain, dryness, and long-term vision issues due to prolonged blue light exposure and reduced blinking. Ophthalmic AI-assisted diagnosis plays a crucial role by analyzing medical images and patient data to detect and predict eye disorders early, allowing for timely intervention and reducing the risk of vision loss. For example, in 2022, 22,552 new certifications for vision impairment were reported in England, with several cases linked to conditions such as diabetic eye disease, glaucoma, and age-related macular degeneration. The growing prevalence of such disorders is a key factor in driving the demand for AI-assisted diagnosis in ophthalmology.

Companies in the ophthalmic AI-assisted diagnosis market are increasingly developing innovative solutions to improve diagnostic accuracy, enhance patient care, and provide predictive insights. One such solution is the ocular data-as-a-service platform, a digital tool that allows ophthalmologists, clinics, and AI diagnostic systems to remotely access, analyze, and share ocular data such as retinal images. This improves diagnosis, monitoring, and research. For instance, in May 2025, Topcon Healthcare Solutions Inc. introduced IDHea, a cloud-based platform designed to streamline ophthalmic diagnostics and improve patient outcomes. By offering fast and secure access to real-world and clinical ocular datasets, IDHea accelerates AI and digital health innovation. It helps researchers generate AI-driven insights to advance both eye and systemic disease care. Built on principles of fast access, safety, and transparency, IDHea facilitates personalized and proactive patient care while ensuring privacy and governance.

In May 2025, Topcon Healthcare Inc. strengthened its AI-driven ophthalmic diagnostic capabilities by acquiring RetInSight GmbH. This acquisition supports the company's objective of advancing global eye care through intelligent diagnostic solutions. RetInSight GmbH, an Austrian medtech company, specializes in AI-assisted ophthalmic diagnostics. With this acquisition, Topcon Healthcare enhances its ability to deliver high-quality eye care, reduce costs, and improve clinical outcomes through innovations in retinal imaging.

Major players in the ophthalmic artificial intelligence-assisted diagnosis market are Canon Medical Systems Corporation, IDx Technologies Inc., Optos PLC, Digital Diagnostics Inc., Ophtai, Oivi Tech Private Limited, Altris Inc., AEYE Health Inc., Eyenuk Inc., JuneBrain Inc., Mediwhale Inc., Mikajaki SA, MONA.health BV, Remidio Innovative Solutions Pvt. Ltd., Retinalyze System A/S, Retinarisk, VoxelCloud Inc., Voxeleron LLC, Ikerian AG, Retmarker, and Synapxe Pte Ltd.

North America was the largest region in the ophthalmic artificial intelligence-assisted diagnosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ophthalmic artificial intelligence-assisted diagnosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ophthalmic artificial intelligence-assisted diagnosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Ophthalmic artificial intelligence-assisted diagnosis refers to the use of AI technologies to analyze eye-related medical data, such as retinal images or patient records, for the detection, diagnosis, or monitoring of eye diseases. It combines algorithms such as machine learning and deep learning with imaging and clinical data to support faster, more accurate, and automated decision-making in ophthalmology.

The primary types of ophthalmic AI-assisted diagnosis systems are cloud-based and on-premises. Cloud-based systems are hosted on remote servers and accessed via the internet. Technologies involved include deep learning, machine learning, natural language processing (NLP), computer vision, and others. These systems are applied in settings such as hospitals, clinics, and imaging centers.

The ophthalmic artificial intelligence-assisted diagnosis market research report is one of a series of new reports that provides ophthalmic artificial intelligence-assisted diagnosis market statistics, including ophthalmic artificial intelligence-assisted diagnosis industry global market size, regional shares, competitors with an ophthalmic artificial intelligence-assisted diagnosis market share, detailed ophthalmic artificial intelligence-assisted diagnosis market segments, market trends and opportunities, and any further data you may need to thrive in the ophthalmic artificial intelligence-assisted diagnosis industry. This ophthalmic artificial intelligence-assisted diagnosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ophthalmic artificial intelligence-assisted diagnosis market includes revenues earned by entities by providing services such as technical support and maintenance, clinical trial support, training and consultation, data management, and annotation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The ophthalmic artificial intelligence-assisted diagnosis market also includes sales of wearable eye-tracking devices, retinal scanners, AI-enabled slit-lamp imaging devices, and portable artificial intelligence ophthalmic diagnostic kits. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.